Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01624506
Other study ID # 2776
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2010
Est. completion date July 2018

Study information

Verified date May 2021
Source Torax Medical Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Anti-Reflux Surgical Study has been established to: - Collect data about anti-reflux surgical treatment options (magnetic sphincter augmentation and Fundoplication) in everyday clinical practice - Track the clinical course of patients from pre-operative assessment to three years post-surgery


Description:

This study will track and monitor patients treated with either the magnetic sphincter augmentation or Fundoplication, making it the first Registry to collect data on both anti-reflux surgical options in the setting of everyday clinical experience.


Recruitment information / eligibility

Status Completed
Enrollment 760
Est. completion date July 2018
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Individuals treated with LINX Reflux Management System or Fundoplication - Individuals who have provided appropriate authorization per institutional policy and procedure to have clinical and health information collected for the Anti-Reflux Surgical Registry. - Individuals willing to complete questionnaires and comply with the three years of follow-up. Exclusion Criteria: - Known circumstances that would make it unlikely for an individual to complete the three year follow-up (e.g. life expectancy <3 years)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Austria Herz Jesu Krankenhaus Vienna
Austria AKH Wien Wien
Germany MIC Klinik Berlin Berlin
Germany Knappschafts Krankenhaus Bottrop Bottrop
Germany Diako Bremen Bremen
Germany Krankenhaus Castrop Rauxel Castrop Rauxel
Germany Klinikum Forchheim Forchheim
Germany Krankenhaus Herne Herne
Germany Marien Krankenhaus Kassel
Germany Uniklinikum Koln Koln
Germany Arabella Klinik Munchen
Germany Ruppiner Kliniken Neuruppin
Germany Stadtkrankenhaus Schwabach Schwabach
Germany St. Rochus Telgte
Germany Ev. K Zweibrucken Zweibrucken
Italy Policlinico San Donato Milan
United Kingdom Reflux Centre Birmingham
United Kingdom Epsom and St. Helier Hospital Epsom
United Kingdom Royal Devon & Exeter Hospital Exeter
United Kingdom Spire Tunbridge Wells Hospital Tunbridge Wells
United Kingdom Weymouth Hospital Weymouth

Sponsors (1)

Lead Sponsor Collaborator
Torax Medical Incorporated

Countries where clinical trial is conducted

Austria,  Germany,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL) Gastroesophageal Reflux Disease Health Related Quality of Life Outcomes (GERD-HRQL) Total scores range from 0-50 (min/max) 10 questions total, each rating 0-5 (min/max) Lower is better; higher is worse 3 years post-surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05561179 - Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease N/A
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Completed NCT01946971 - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) Phase 1/Phase 2
Recruiting NCT01825473 - Study of Erythromycin in GER-Associated Apnea of the Newborn N/A
Completed NCT00614536 - Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period Phase 4
Completed NCT00365300 - Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) Phase 3
Completed NCT00373997 - Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Phase 4
Completed NCT00284908 - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers Phase 1
Completed NCT01167543 - Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease N/A
Completed NCT00291746 - Validation of RDQ Questionnaire Phase 4
Completed NCT00226044 - Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. Phase 3
Completed NCT00567021 - German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms N/A
Completed NCT00141960 - Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease Phase 2/Phase 3
Completed NCT00215787 - Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease N/A
Completed NCT00181805 - Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
Completed NCT01048840 - Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
Terminated NCT01281553 - A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease Phase 4
Completed NCT05486169 - Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy N/A
Completed NCT04034017 - Gastroesophageal Reflux Disease Among College Students
Terminated NCT03226054 - Determining Risk Factors for Successful PPI Weaning N/A